CYP2C18: the orphan in the CYP2C family

References

• 1. https://cpicpgx.org/guidelines/
  Google Scholar
• 2. Whirl-Carrillo M, Huddart R, Gong L et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol. Ther. 110(3), 563–572 (2021).
  MedlineGoogle Scholar
• 3. www.pharmgkb.org/pathway/PA145011113
  Google Scholar
• 4. www.pharmgkb.org/pathway/PA153627759
  Google Scholar
• 5. www.pharmgkb.org/pathway/PA152530846
  Google Scholar
• 6. www.pharmgkb.org/pathway/PA145011113
  Google Scholar
• 7. www.pharmgkb.org/pathway/PA166163705
  Google Scholar
• 8. www.pharmgkb.org/pathway/PA166247041
  Google Scholar
• 9. www.pharmgkb.org/pathway/PA166160830
  Google Scholar
• 10. Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of atomoxetine biotransformation and implications for development of PBPK models for dose individualization in children. Drug Metab. Dispos. 44(7), 1070–1079 (2016).
  Medline CASGoogle Scholar
• 11. Läpple F, von Richter O, Fromm MF et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13(9), 565–575 (2003).
  MedlineGoogle Scholar
• 12. Gaedigk A, Casey ST, Whirl-Carrillo M, Miller NA, Klein TE. Pharmacogene Variation Consortium: a global resource and repository for pharmacogene variation. Clin. Pharmacol. Ther. 110(3), 542–545 (2021).
  MedlineGoogle Scholar
• 13. Gaedigk A, Ingelman-Sundberg M, Miller NA et al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin. Pharmacol. Ther. 103(3), 399–401 (2018).
  Medline CASGoogle Scholar
• 14. Sangkuhl K, Claudio-Campos K, Cavallari LH et al. PharmVar GeneFocus: CYP2C9. Clin. Pharmacol. Ther. 110(3), 662–676 (2021).
  Medline CASGoogle Scholar
• 15. Botton MR, Whirl-Carrillo M, Del Tredici AL et al. PharmVar GeneFocus: CYP2C19. Clin. Pharmacol. Ther. 109(2), 352–366 (2021).
  MedlineGoogle Scholar
• 16. Gaedigk A, Boone EC, Scherer SE et al. CYP2C8, CYP2C9, and CYP2C19 characterization using next-generation sequencing and haplotype analysis: a GeT-RM collaborative project. J. Mol. Diagn. 24(4), 337–350 (2022).
  Medline CASGoogle Scholar
• 17. Bråten LS, Haslemo T, Jukic MM et al. A novel CYP2C haplotype associated with ultrarapid metabolism of escitalopram. Clin Pharmacol. Ther. 110(3), 786–793 (2021).
  MedlineGoogle Scholar
• 18. Kee PS, Maggo SDS, Kennedy MA et al. Omeprazole treatment failure in gastroesophageal reflux disease and genetic variation at the CYP2C locus. Front. Genet. 13, 869160 (2022).
  Medline CASGoogle Scholar
• 19. www.ebi.ac.uk/Tools/psa/emboss_stretcher/
  Google Scholar
• 20. www.proteinatlas.org/
  Google Scholar
• 21. www.gtexportal.org/home/
  Google Scholar
• 22. Uhlén M, Fagerberg L, Hallström BM et al. Tissue-based map of the human proteome. Science 347(6220), 1260419 (2015).
  MedlineGoogle Scholar
• 23. Wenzel C, Drozdzik M, Oswald S. Mass spectrometry-based targeted proteomics method for the quantification of clinically relevant drug metabolizing enzymes in human specimens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1180, 122891 (2021).
  Medline CASGoogle Scholar
• 24. Takayama K, Ito K, Matsui A et al. In vivo gene expression profile of human intestinal epithelial cells: from the viewpoint of drug metabolism and pharmacokinetics. Drug Metab. Dispos. 49(3), 221–232 (2021).
  Medline CASGoogle Scholar
• 25. Miyauchi E, Tachikawa M, Declèves X et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol. Pharm. 13(8), 2631–2640 (2016).
  Medline CASGoogle Scholar
• 26. Wu Y, Chitranshi P, Loukotková L et al. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells. Arch. Toxicol. 91(6), 2405–2423 (2017).
  Medline CASGoogle Scholar
• 27. Fang WB, Lofwall MR, Walsh SL, Moody DE. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography–electrospray ionization–tandem mass spectrometry in human matrices: in vivo and in vitro applications. J. Anal. Toxicol. 37(6), 337–344 (2013).
  MedlineGoogle Scholar
• 28. Yamane M, Kawashima K, Yamaguchi K et al. In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica 45(3), 230–238 (2015).
  Medline CASGoogle Scholar
• 29. Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem. Pharmacol. 153, 196–204 (2018).
  Medline CASGoogle Scholar
• 30. Maagdenberg H, Bierings MB, van Ommen CH et al. The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study. J. Thromb. Haemost. 16(9), 1732–1742 (2018).
  Medline CASGoogle Scholar
• 31. Collins JM, Wang D. Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism. Pharmacogenet. Genomics 32(1), 16–23 (2022).
  Medline CASGoogle Scholar
• 32. Tang X, Chen S. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr. Drug Metab. 16(2), 86–96 (2015).
  Medline CASGoogle Scholar
• 33. Yu D, Green B, Tolleson WH et al. MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. Biochem. Pharmacol. 98(1), 215–223 (2015).
  Medline CASGoogle Scholar
• 34. Zhang S-Y, Surapureddi S, Coulter S, Ferguson SS, Goldstein JA. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol. Pharmacol. 82(3), 529–540 (2012).
  Medline CASGoogle Scholar